Basecamp Research, a frontier AI lab harnessing evolution to design new medicines, today announced the first AI models capable of programmable gene insertion, offering a new way to replace faulty genes and reprogramme cells for therapeutic use.
Trained in collaboration with NVIDIA, these models are driving the development of a new generation of treatments for cancer and inherited diseases. In parallel, Basecamp Research secured an investment from NVentures (NVIDIA's venture capital arm).
The same versatile model also helped design novel antimicrobial peptide molecules with a 97% lab-confirmed success rate, including candidates that appeared highly potent against multidrug-resistant superbugs.
The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of curative cell and gene therapies. Developed by training the largest evolutionary AI models on a new, globally collected dataset, accelerated by NVIDIA BioNeMo.
